OLMA

Stats

Summary

olema oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. our lead program, op-1250, a potential best-in-class complete estrogen receptor antagonist (ceran), is in development to treat estrogen receptor-positive (er+), human epidermal growth factor receptor 2-negative (her2-) breast cancer. olema recently initiated a phase 1/2 dose-escalation and expansion clinical trial of op-1250. we are supported in our mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies. for more information about the company please visit www.olema.com.

Market Cap: 788 Million

Primary Exchange: NASDAQ

Website: olemapharma.com

Shares Outstanding: 55.1 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 1.3010685971188172

Sector: Manufacturing

Industry: Pharmaceutical Preparation Manufacturing

Ethical Flags

Longest drawdown: 342 trading days

From: 2021-02-19 To: 2024-03-07

Lowest Point:

Ex-Date	Payment Date	Record Date	Declared Date	Amount	Flag	Dividend Type	Qualified	Indicated

Ex-Date	Declared Date	Record Date	Payment Date	Ratio	To Factor	For Factor